Company news
Rhythm Biosciences Limited (ASX:RHY) news
Rhythm Biosciences Limited news releases on 6ix. Latest, Apr 24, 2024: Dr David Atkins appointed Chief Executive Officer of Rhythm
Press releases — page 2
Dr David Atkins appointed Chief Executive Officer of Rhythm
April 24, 2024
Rhythm Maintains ISO Certification
April 22, 2024
Close of Rights Issue
March 20, 2024
Internationally Renowned Clinical Advisory Board Established
March 18, 2024
S&P DJI Announces March 2024 Quarterly Rebalance
March 1, 2024
Half Yearly Report and Accounts
February 28, 2024
Prospectus - 2024 Non-Renounceable Rights Issue
February 18, 2024
Rights Issue Offer to Raise Up To $6.6 million
February 8, 2024
Quarterly Activities Report and Appendix 4C - Dec23
January 30, 2024
Strategy & Market Update
December 17, 2023
Platform Expansion - Lung Cancer Diagnostic Test Update
November 23, 2023
Executive Management Changes
November 15, 2023
Receipt of First Tranche of $1.69m in R&D Tax Incentive
November 13, 2023
Response to ASX Query
October 18, 2023
RHY 2023 AGM Presentation
October 9, 2023
Investor Presentation
June 19, 2023
UK Strategic Partnership with LINK Medical Solutions
May 24, 2023
UK CA Mark granted for ColoSTAT
May 16, 2023
Executive Management Change
April 19, 2023
ColoSTAT abstracts accepted at 2023 ASCO Annual Meeting
April 6, 2023
Reinstatement to Official Quotation
March 5, 2023
Update to TGA Submission
March 5, 2023
Suspension from Official Quotation
March 3, 2023
Appendix 4D & Interim Financial Report
February 23, 2023
RHY Institutional Presentation
February 23, 2023
Appendix 4C - Quarterly
January 31, 2023
Institutional Presentation
January 24, 2023
Market Update
December 14, 2022
RHY Continues Platform Expansion Program for Other Cancers
December 14, 2022
MST Access Diagnostics Forum Presentation (Amended)
December 6, 2022
MST Access Financial Diagnostics Presentation
December 5, 2022
RHY 2022 AGM Presentation
November 29, 2022
Healthcare Conference Investor Presentation
November 8, 2022
ColoSTAT Authorised For Sale In New Zealand
November 2, 2022
Rhythm Receives $2.7m R&D Tax Incentive
October 20, 2022
Director Share Sale To Institutional Funds Manager
September 8, 2022
RHY Advances Platform Expansion with Other Cancers
July 18, 2022
Rhythm Biosciences : Application for quotation of securities - RHY
June 19, 2022
Completion of Final TGA Submission Step to Approve ColoSTAT
May 11, 2022
Rhythm Closes Final Clinical Trial Site
May 3, 2022
Appendix 4C - quarterly
April 27, 2022
Rhythm Biosciences : RHY Presentation at PAC Partners Healthcare Conference
April 5, 2022
Rhythm Biosciences - Investor Presentation
April 4, 2022
Study 7 Confirms ColoSTAT Meets Primary Endpoint
April 3, 2022
S&P DJI Announces March 2022 Quarterly Rebalance
March 4, 2022
Rhythm Biosciences - Investor Webinar Presentation
March 1, 2022
Appendix 4D and Half Yearly Report and Accounts
February 24, 2022
Rhythm Maintains Ongoing ISO13485 Certification
February 14, 2022
Placement of $6.5m to Global Institutional Funds Manager
January 5, 2022
RHY Platform Technology Targets Five Cancers
December 13, 2021